阿摩線上測驗
26.下列何種cytotoxic agents之致吐風險為高風險等級（＞90%）？
(A)bleomycin
(B)cetuximab
(C)cisplatin ＞50 mg/m2
(D)etoposide
統計： A(82), B(51), C(4553), D(245), E(0) #1742755
詳解 (共 10 筆)
致吐性
High (>90%) | Cisplatin、Mechlorethamine、Cyclophophamide≥1500mg/m2 Carmustine、Dacarbazine、Dactinomycin |
Moderate (30-90%) | Oxalipatin、Cytarabine>1g/m2、Carboplatin、Ifosfamide、 Cyclophosphamide<1500mg/m2、Anthracycline、Irinotecan |
Low (10-30%) | Paclitaxel、Docetaxel、Topotecan、Etoposide、MTX、 Mitomycin、Mitoxantrone Cytarabine≤1g/m2、5-FU、Cetuximab、Trastuzumab |
Minimal (<10%) | Bleomycin、Busulfan、Vincristine、Vinblastine、 Vinorelbine、Bevacizumab |
*高致吐性
A: anthracycline [Doxorubicin, Epirubicin, Idarubicin ] high &delayed CINV
C: Carboplatin [cisplatin ≥50mg/m2] high &delayed CINV (oxaliplatin = moderate)
C: Cyclophosphamide ≥1500mg/m2 &delayed CINV
Emetogenicity of Selected Antineoplastic Agents(抗腫瘤製劑之致嘔吐性)
| High Emetogenicity(>90%) | Moderate Emetogenicity(30%~90%) | Low Emetogenicity(10%~30%) | Minimal Emetogenicity(<10%) |
Cisplatin(IV)(≥50mg/m2) Cyclophosphamide(IV)(≥1500mg/m2) Procarbazine(PO) Dacarbazine(IV) Mechorethamine(IV) | Cisplatin(IV)(<50mg/m2) Cyclophosphamide(IV)(<1500mg/m2) | Lapatinib(PO) | Erlotinib(PO) Gefitinib(PO) Sorafenib(PO) Sunitinib(PO) |
Dactinomycin(IV) Doxorubicin+ Cyclophosphamide(IV) Epirubicin+ Cyclophosphamide(IV) | Daunorubicin(IV) Doxorubicine(IV) Idarubicine(IV) | Vinblastine(IV) Vincristine(IV) Vinorelbine(IV) | |
Etoposide(PO) | Etoposide(IV) Paclitaxel(IV) Docetaxel(IV) | ||
Methotrexate(IV)(>1g/m2) Cytarabine(IV)(>1g/m2) | Methotrexate(IV)(<1g/m2) Pemetrexed(IV) Cytarabine(IV)(<1g/m2) Gemcitabine(IV) Capecitabine(PO) Fluorouracil(IV) | Methotrexate(PO) | |
Trastuzumab(IV) Cetuximab(IV) | Bevacizumab(IV) Bleomycin(IV) Thalidomide(PO) |
7F cyclophosphamide 應該是大於等於1500而不是15000
